{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T12:41:43Z","timestamp":1777380103048,"version":"3.51.4"},"reference-count":40,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["AIDS Research and Human Retroviruses"],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:p>\n                    Aim of this study was to assess the predictors of virological failure (VF) among patients living with HIV (PLWHIV) switching from an effective first-line antiretroviral therapy (ART) regimen, and to evaluate the emergence of resistance-associated mutations. All adult patients enrolled in the Antiviral Response Cohort Analysis cohort who started ART after 2010, with at least 6 months of virological suppression (VS) before ART switch and with an available genotypic resistance test (GRT) at baseline were included. Thirty-two patients out of the 607 PLWHIV included (5.3%) experienced VF after a median of 11 months from ART switch. Younger age (adjusted Hazard Ratio [aHR] 0.96, 95% confidence interval [CI] 0.92\u20130.99,\n                    <jats:italic toggle=\"yes\">p<\/jats:italic>\n                    \u2009=\u2009.023), being male who have sex with male (aHR 0.15, 95% CI 0.03\u20130.69,\n                    <jats:italic toggle=\"yes\">p<\/jats:italic>\n                    \u2009=\u2009.014), and longer time from VS to ART switch (aHR 0.97, 95% CI 0.95\u20131.00,\n                    <jats:italic toggle=\"yes\">p<\/jats:italic>\n                    \u2009=\u2009.021) resulted protective toward VF, while receiving a first-line regimen containing a backbone other than ABC\/3TC or TXF\/FTC (aHR 3.61, 95% CI 1.00\u201313.1,\n                    <jats:italic toggle=\"yes\">p<\/jats:italic>\n                    \u2009=\u2009.050) and a boosted protease inhibitor as anchor drug (aHR 3.34, 95% CI 1.20\u20139.28,\n                    <jats:italic toggle=\"yes\">p<\/jats:italic>\n                    \u2009=\u2009.021) were associated with higher risk of VF. GRT at the moment of VF was available only for 13 patients (40.6%). ART switch in patients with stable control of HIV infection is a safe practice, even if particular attention should be paid in certain cases of patients switching from regimens containing low-performance backbones or protease inhibitors.\n                  <\/jats:p>","DOI":"10.1089\/aid.2021.0016","type":"journal-article","created":{"date-parts":[[2021,12,31]],"date-time":"2021-12-31T00:18:02Z","timestamp":1640909882000},"page":"463-471","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Predictors of Virological Failure Among People Living with HIV Switching from an Effective First-Line Antiretroviral Regimen"],"prefix":"10.1177","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6343-3271","authenticated-orcid":false,"given":"Laura","family":"Magnasco","sequence":"first","affiliation":[{"name":"Infectious Diseases Unit, Ospedale Policlinico San Martino \u2013 IRCCS per l'Oncologia, Genoa, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachele","family":"Pincino","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Ospedale Policlinico San Martino \u2013 IRCCS per l'Oncologia, Genoa, Italy."},{"name":"Department of Health's Sciences, University of Genoa, Genoa, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Pasculli","sequence":"additional","affiliation":[{"name":"Department of Computer, Control, and Management Engineering Antonio Ruberti (DIAG), La Sapienza University, Rome, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yagai","family":"Bouba","sequence":"additional","affiliation":[{"name":"Department of Experimental Medicine, University of Rome \u201cTor Vergata,\u201d Rome, Italy."},{"name":"Chantal BIYA International Reference Centre for Research on HIV\/AIDS Prevention and Management (CIRCB), Yaound\u00e9, Cameroon."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Saladini","sequence":"additional","affiliation":[{"name":"Department of Medical Biotechnologies, University of Siena, Siena, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davide Fiore","family":"Bavaro","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences and Human Oncology, Clinic of Infectious Diseases, University of Bari \u201cAldo Moro,\u201d Bari, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"De Vito","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases, Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rossana","family":"Lattanzio","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences and Human Oncology, Clinic of Infectious Diseases, University of Bari \u201cAldo Moro,\u201d Bari, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Romina","family":"Corsini","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, AUSL \u2013 IRCCS Reggio Emilia, Reggio Emilia, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizio","family":"Zazzi","sequence":"additional","affiliation":[{"name":"Department of Medical Biotechnologies, University of Siena, Siena, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Incardona","sequence":"additional","affiliation":[{"name":"InformaPRO s.r.l., Rome, Italy \u2013 EuResist Network GEIE, Rome, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Rossetti","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Azienda Ospedaliero-Universitaria Senese, Siena, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9921-3684","authenticated-orcid":false,"given":"Antonia","family":"Bezenchek","sequence":"additional","affiliation":[{"name":"InformaPRO s.r.l., Rome, Italy \u2013 EuResist Network GEIE, Rome, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanni","family":"Borghi","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Azienda Ospedaliero-Universitaria Policlinico of Modena, Modena, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1436-5089","authenticated-orcid":false,"given":"Antonio","family":"Di Biagio","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Ospedale Policlinico San Martino \u2013 IRCCS per l'Oncologia, Genoa, Italy."},{"name":"Department of Health's Sciences, University of Genoa, Genoa, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2022,6,6]]},"reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000002603"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001408"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0167492"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1728"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1080\/23744235.2017.1410285"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1080\/23744235.2018.1554908"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000000849"},{"key":"e_1_3_5_9_2","unstructured":"GmbH B : EACS Guidelines. EACSociety. Available at https:\/www.eacsociety.org\/guidelines\/eacs-guidelines\/eacs-guidelines.html accessed October27 2020."},{"key":"e_1_3_5_10_2","unstructured":"Della SM: Guidelines on antiretroviral therapy. Available at http:\/\/www.salute.gov.it\/portale\/hiv\/dettaglioContenutiHIV.jsp?lingua=italiano&id=187&area=aids&menu=vuoto accessed October27 2020."},{"key":"e_1_3_5_11_2","unstructured":"BHIVA guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015 (2016 interim update). Available at https:\/\/www.bhiva.org\/HIV-1-treatment-guidelines accessed October27 2020."},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001964"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32832ba8ec"},{"key":"e_1_3_5_14_2","first-page":"111","article-title":"2019 update of the drug resistance mutations in HIV-1","volume":"27","author":"Wensing AM","year":"2019","unstructured":"Wensing AM, , Calvez V, , Ceccherini-Silberstein F, et al.: 2019 update of the drug resistance mutations in HIV-1. Top Antivir Med, 2019; 27:111\u2013121.","journal-title":"Top Antivir Med"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1089\/apc.2017.0140"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2018.00063"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003325"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000016813"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(19)30149-3"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz255"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2018.1478726"},{"key":"e_1_3_5_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky062"},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx018"},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofw141"},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.3851\/IMP3010"},{"key":"e_1_3_5_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.12183"},{"key":"e_1_3_5_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa018"},{"key":"e_1_3_5_28_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000002331"},{"key":"e_1_3_5_29_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa319"},{"key":"e_1_3_5_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25227"},{"key":"e_1_3_5_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.12759"},{"key":"e_1_3_5_32_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky123"},{"key":"e_1_3_5_33_2","first-page":"1163","article-title":"Treatment simplification to atazanavir\/ritonavir + lamivudine versus maintenance of atazanavir\/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M)","volume":"72","author":"Di Giambenedetto S","year":"2017","unstructured":"Di Giambenedetto S, , Fabbiani M, , Quiros Roldan E, et al.: Treatment simplification to atazanavir\/ritonavir + lamivudine versus maintenance of atazanavir\/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M). J Antimicrob Chemother, 2017; 72:1163\u20131171.","journal-title":"J Antimicrob Chemother"},{"key":"e_1_3_5_34_2","doi-asserted-by":"publisher","DOI":"10.7448\/IAS.17.4.19817"},{"key":"e_1_3_5_35_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-019-3934-2"},{"key":"e_1_3_5_36_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-019-3852-3"},{"key":"e_1_3_5_37_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix015"},{"key":"e_1_3_5_38_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-015-1270-8"},{"key":"e_1_3_5_39_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy113"},{"key":"e_1_3_5_40_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu585"},{"key":"e_1_3_5_41_2","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2011.0245"}],"container-title":["AIDS Research and Human Retroviruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/aid.2021.0016","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/aid.2021.0016","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/aid.2021.0016","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T09:16:26Z","timestamp":1777367786000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.1089\/aid.2021.0016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["10.1089\/aid.2021.0016"],"URL":"https:\/\/doi.org\/10.1089\/aid.2021.0016","relation":{},"ISSN":["0889-2229","1931-8405"],"issn-type":[{"value":"0889-2229","type":"print"},{"value":"1931-8405","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6]]}}}